Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
- Receivables Turnover
- The receivables turnover ratio shows significant variability across the observed periods. Starting at 14.12 in March 2019, it declined sharply to a low of 3.96 in September 2019 before recovering and peaking at 33.46 by September 2021. After this peak, there is considerable fluctuation, with extremely high values such as 643.46 in March 2023 followed by a steep decline to 3.13 by September 2023. This suggests irregularity in the speed of collecting receivables, with periods of both efficient and very slow collections.
- Payables Turnover
- The payables turnover ratio also exhibits pronounced fluctuations. Initially, it increased from 8.37 in March 2019 to 13.62 in June 2019, followed by alternating rises and falls. Notably, very low values of 0.79 and 0.57 are observed in September and December 2023, indicating a substantial slowdown in paying off suppliers towards the end of the period. Overall, the pattern reveals inconsistent payment practices with some phases of quick payables settlement and others of delayed payments.
- Working Capital Turnover
- Working capital turnover remains relatively stable but low, generally ranging between 0.1 and 0.22 from March 2019 through September 2022. Occasionally lower values, such as 0.02 in September and December 2023, indicate diminished efficiency in using working capital to generate sales during those periods. Overall, the turnover ratio suggests limited improvement in working capital utilization efficiency over time with a tendency to decline in the latest periods.
- Average Receivable Collection Period
- The average receivable collection period exhibits a downward trend from 92 days in September 2018 to a minimum of 1 day in March 2023, implying an improvement in collecting receivables promptly. However, this trend is interrupted by spikes such as 269 days in March 2022 and 117 days in September 2023, signifying occasional delays or issues in receivables collection. Variability in this metric highlights inconsistencies in the company’s credit management process.
- Average Payables Payment Period
- The average payables payment period shows wide fluctuations, starting at 44 days in March 2019, increasing dramatically to 275 days in September 2021, and peaking at 644 days in December 2023. These extended payment periods towards the end of the timeline convey a tendency to delay payments significantly. Values vary substantially throughout, reflecting irregular cash outflows and possible liquidity management challenges.
Turnover Ratios
Average No. Days
Receivables Turnover
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Accounts receivable | ||||||||||||||||||||||||||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Receivables turnover1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Receivables turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Accounts receivable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenues
- The revenue data exhibits significant volatility over the period analyzed. From March 2018 to December 2018, there was an overall increase, peaking in September 2018 at 10,641 thousand USD, before declining towards the end of 2018. The revenue then declined further through 2019, reaching a low point in December 2019 of 5,212 thousand USD. In 2020, revenues were irregular, with a notable spike of 41,688 thousand USD in September 2020 followed by a return to lower levels in subsequent quarters. This pattern repeats with a substantial increase to 55,600 thousand USD in December 2021, followed by another sharp decline thereafter. The data suggests sporadic large revenue events or perhaps one-time gains amidst generally lower recurring revenues.
- Accounts Receivable
- The accounts receivable figures also display high variability, with some quarters exhibiting unusually high values. Initial values in early 2018 were very low, followed by a spike to 9,156 thousand USD in September 2018. Subsequently, accounts receivable declined through 2019 but again showed irregular increases, such as 5,183 thousand USD in March 2022. Later quarters show fluctuating values with several quarters showing substantial increases, such as 60,056 thousand USD in June 2022, and significant decreases thereafter. This instability may indicate inconsistent collection patterns or recognition of revenue.
- Receivables Turnover Ratio
- The receivables turnover ratio, where available, points to fluctuating efficiency in collecting accounts receivable. The ratio peaked at 76.61 in September 2022 and 643.46 in March 2023, indicating rapid collection in those periods. However, prior to that, ratios varied substantially, trending upward from values around 3.96 in September 2019 to values in the teens or twenties in 2020 and 2021. Low turnover ratios in some earlier periods imply slower collection of receivables, which corresponds with high accounts receivable balances seen in those periods. The spikes in turnover ratios towards recent quarters may reflect unusually low receivables balances or one-time collection events.
- Overall Trends and Insights
- The data reveals pronounced volatility in both revenues and accounts receivable, with episodic large revenue realizations that coincide with sizeable accounts receivable fluctuations. This pattern may suggest cyclical or milestone-driven revenue recognition rather than steady operational revenue. The receivables turnover ratio's variability supports the interpretation of inconsistent collection patterns. Such fluctuations can affect liquidity and operational predictability, implying the necessity for close management attention to receivables and revenue recognition policies. The absence of consistent trends over time points to potential irregularities or project-based revenue streams that are characteristic of companies involved in development or research sectors.
Payables Turnover
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Accounts payable | ||||||||||||||||||||||||||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Payables turnover1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Payables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Payables turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenues
- Revenues exhibit significant volatility over the observed quarters, with values ranging from a low of 378 thousand US dollars in the most recent quarter to a peak of 89,968 thousand US dollars in September 2022. There is no clear upward or downward trend; instead, revenues fluctuate sharply, indicating potential seasonality or irregular income streams. Periods such as the third quarter of 2020 and the fourth quarter of 2021 show substantial spikes. Conversely, multiple periods have revenues under 10,000 thousand US dollars, suggesting inconsistency in revenue generation.
- Accounts Payable
- Accounts payable also show considerable variation, ranging from 1,336 thousand US dollars to a high of 25,611 thousand US dollars in March 2023. The data indicates increased liabilities towards the latter periods, particularly from mid-2020 onward. The highest figures are clustered between late 2021 and early 2023, suggesting either delayed payments to suppliers or an expansion in procurement on credit terms. Earlier periods present lower and more fluctuating payables, with occasional spikes.
- Payables Turnover Ratio
- The payables turnover ratio displays inconsistent fluctuations with values spanning from a low of 0.57 to a high of 13.62 during the covered span. Higher ratios generally indicate quicker payment to suppliers; thus, the lower values in recent quarters, especially falling below 1, suggest significantly slower payments or longer credit terms. There is a noticeable decline in this ratio in later periods compared to earlier values, possibly reflecting changes in working capital management or supplier relationship strategies.
- Overall Financial Patterns
- The financial data suggests substantial variability in both revenues and accounts payable, with no stable trend of growth or decline over the quarters. The sharp fluctuations in revenues may imply volatile demand or irregular product launches. Simultaneously, rising accounts payable levels combined with declining payables turnover ratios in recent quarters indicate a tendency towards extended payment timelines or increased credit reliance. This pattern could reflect strategic cash flow management or liquidity challenges. The mismatch between revenue spikes and payables changes points to complex operational dynamics affecting the company's financial management.
Working Capital Turnover
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Current assets | ||||||||||||||||||||||||||||||
Less: Current liabilities | ||||||||||||||||||||||||||||||
Working capital | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Working capital turnover1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Working capital turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Working Capital
- The working capital shows considerable fluctuations over the analyzed quarters. Starting at approximately 234 million USD in March 2018, it experienced a gradual decline reaching a low of about 155 million USD by September 2019. Subsequently, there was a notable recovery and growth phase, peaking at around 808 million USD in September 2022. After this peak, the working capital exhibited a decreasing trend, falling to approximately 484 million USD by September 2023. Overall, the pattern indicates cycles of contraction and expansion, with a significant peak in late 2022 before a recent decline.
- Revenues
- Revenues demonstrated high volatility throughout the period. From modest levels around 5 to 10 million USD in early 2018 and 2019, revenues experienced an exceptional spike in September 2020, reaching about 41.7 million USD, which is a distinct outlier compared to other periods. Post this spike, revenues largely declined and fluctuated at lower levels, with occasional moderate increases, such as in June 2021 (approximately 55.6 million USD) and September 2022 (nearly 89 million USD). The general trend after 2020 suggests inconsistent performance with sharp peaks, followed by rapid decreases. The recent quarters in 2023 show markedly low revenue figures below 5 million USD.
- Working Capital Turnover
- The working capital turnover ratio remains low overall, indicating limited revenue generation relative to the working capital base. This ratio ranges mostly between 0.02 and 0.28 across the quarters. Notably, the turnover ratio reached its highest in September 2022 at 0.28, correlating with the peak in revenues during the same period. Conversely, the ratio is at its lowest levels (0.02) in some recent quarters such as June and September 2023, reflecting low revenue relative to working capital. These fluctuations suggest intermittent improvements in working capital efficiency but no sustained upward trend.
- Summary and Insights
- The financial data reveals a pattern of volatility both in working capital and revenues. Working capital expanded significantly towards late 2021 and peaked in 2022 before receding, while revenue spikes occur sporadically without a consistent growth trajectory. The working capital turnover ratio remains generally low, implying constrained efficiency in using working capital to generate sales. The pronounced spikes in revenue could indicate irregular or one-off events impacting performance. Recent quarters demonstrate reduced revenues alongside decreasing working capital turnover, warranting attention to operational efficiency and revenue generation strategies.
Average Receivable Collection Period
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||||||||||||||
Receivables turnover | ||||||||||||||||||||||||||||||
Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
Average receivable collection period1 | ||||||||||||||||||||||||||||||
Benchmarks (no. days) | ||||||||||||||||||||||||||||||
Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Receivables Turnover Ratio Trends
- The receivables turnover ratio displays significant variability across the observed periods. Initial data points are missing, but starting from March 31, 2018, the ratio is recorded at 14.12, which then declines to a low of 1.36 by March 31, 2022. Subsequently, the ratio exhibits sharp increases, reaching an exceptionally high peak of 643.46 in March 31, 2023, before decreasing again to 3.13 by September 30, 2023. This extreme volatility suggests fluctuations in the efficiency with which the company collects its receivables. The spikes in turnover ratio could indicate periods of rapid collection or possibly data anomalies, while the low points may reflect challenges in receivables collection or longer sales cycles.
- Average Receivable Collection Period Trends
- The average collection period in days shows an inverse relationship with the receivables turnover ratio, consistent with typical financial principles. Beginning from March 31, 2018, the collection period increases from 26 days to a peak of 269 days at March 31, 2022. Prior to this peak, the period fluctuates between approximately 17 to 92 days, indicating moderate efficiency in receivable collection. The spike to 269 days marks a significant deterioration in collection efficiency. Following this, the collection period sharply drops to as low as 1 day by March 31, 2023, aligning with the corresponding peak in receivables turnover. Afterward, the interval extends again to 117 days by September 30, 2023. These pronounced swings imply instability in the company's credit and collection processes or irregularities in billing cycles.
- Summary of Insights
- The data indicates pronounced instability in both the receivables turnover and the average collection period. Such fluctuations may reflect changes in credit policies, varying customer payment behaviors, or irregular accounting practices. The extreme peaks and troughs observed suggest episodic acceleration or delays in cash collections rather than a steady operational trend. This volatility merits further investigation to determine underlying causes and to enhance predictability and management of working capital.
Average Payables Payment Period
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||||||||||||||
Payables turnover | ||||||||||||||||||||||||||||||
Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
Average payables payment period1 | ||||||||||||||||||||||||||||||
Benchmarks (no. days) | ||||||||||||||||||||||||||||||
Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of the payables turnover ratio over the reported periods reveals significant fluctuations. Beginning in the first quarter of 2019, the ratio showed a high value of 8.37, increasing further to a peak of 13.62 in the second quarter of 2019. This peak was followed by several periods of volatility, with ratios declining to as low as 1.33 by the fourth quarter of 2021. Subsequently, the ratio recovered somewhat, reaching values above 10 in the first half of 2022 before declining sharply again in 2023, falling below 1 in the last two reported quarters.
Correspondingly, the average payables payment period, expressed in days, exhibited an inverse trend relative to the payables turnover ratio, as expected due to the nature of these metrics. Starting from 44 days in the first quarter of 2019, the period shortened to 27 days by the second quarter of 2019, indicating faster payment cycles. However, it then lengthened substantially, reaching an extreme high of 275 days by the fourth quarter of 2021. This was followed by a reduction to about 34-36 days in the first half of 2022, but then it experienced another steep increase to 461 and 644 days in the first and second quarters of 2023, respectively. These extended payment periods suggest a significant slowdown in settling payables in the latest quarters.
Overall, the data indicate considerable volatility in the company's management of payables, with periods of both swift and very extended payment timelines. The recent markedly low payables turnover ratios combined with extremely high average payment periods may point to potential liquidity or operational challenges affecting the timely payment of liabilities.
- Payables Turnover Ratio
- Showed a peak in mid-2019, followed by significant declines through 2021, partial recovery in early 2022, and a sharp downturn thereafter.
- Average Payables Payment Period
- Varied inversely with turnover ratio; notable shortening in mid-2019, then dramatic extensions peaking at over 600 days in mid-2023.
- Trend Implications
- Recent increases in payment periods alongside low turnover ratios suggest delayed payments, possibly indicating liquidity constraints or altered payment policies.